vatalanib has been researched along with laq824 in 1 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (laq824) | Trials (laq824) | Recent Studies (post-2010) (laq824) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 70 | 1 | 19 |
| Protein | Taxonomy | vatalanib (IC50) | laq824 (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.0607 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.0848 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.0512 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.3987 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.0506 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.0309 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.0303 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.0974 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.0545 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.0308 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.0569 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atadja, P; Kachhap, SK; Kato, Y; Pili, R; Qian, DZ; Wang, X; Wei, Y; Zhang, L | 1 |
1 other study(ies) available for vatalanib and laq824
| Article | Year |
|---|---|
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cattle; Cell Division; Cell Line, Tumor; Drug Synergism; Endothelium, Vascular; Enzyme Inhibitors; Gene Expression Regulation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Neovascularization, Pathologic; Phthalazines; Pyridines; Transcription Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2004 |